Beyond Hepatocellular Carcinoma and Colorectal Metastasis: The Expanding Applications of Radioembolization

Zurkiya, Omar; Ganguli, Suvranu

doi:10.3389/fonc.2014.00150

Cited by 11 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such examples would include metastases from breast, uveal melanoma, neuroendocrine tumours, sarcoma, oesophageal, endometrial, lung, ovarian and squamous cell carcinoma of the anus. 37,38 In spite of its relatively recent development, radioembolization has yielded great promise and potential as a safe and efficacious treatment for locally advanced liver cancer. 39,40 In both salvage and first-line therapy, radioembolization has demonstrated high response rates.…”

Section: Radioembolization: Clinical Indications Efficacy and Considmentioning

confidence: 99%

Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry

Tong¹,

Kao²,

Too³

et al. 2016

BJR

View full text Add to dashboard Cite

In recent years, yttrium-90 ((90)Y) microsphere radioembolization has been establishing itself as a safe and efficacious treatment for both primary and metastatic liver cancers. This extends to both first-line therapies as well as in the salvage setting. In addition, radioembolization appears efficacious for patients with portal vein thrombosis, which is currently a contraindication for surgery, transplantation and transarterial chemoembolization. This article reviews the efficacy and expanding use of (90)Y microsphere radioembolization with an added emphasis on recent advances in personalized dosimetry and interventional radiology techniques. Directions for future research into combination therapies with radioembolization and expansion into sites other than the liver are also explored.

show abstract

Section: Radioembolization: Clinical Indications Efficacy and Considmentioning

confidence: 99%

Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry

Tong¹,

Kao²,

Too³

et al. 2016

BJR

View full text Add to dashboard Cite

show abstract

“…Furthermore, chemotherapy with mitotane, used as the mainstay treatment, yields response rates of only up to 31% [7]. Treatment of metastatic liver disease with surgical resection, percutaneous ablation, and endovascular chemoembolization has also been attempted, with variable success rates debated [8]. Clearly, these techniques would prove of limited use in the setting of diffuse liver metastatic disease.…”

Section: Casementioning

confidence: 99%

Yttrium-90 Radioembolization of Metastatic Adrenocortical Carcinoma to the Liver following Systemic Chemotherapy and Surgical Resection of the Primary Lesion

et al. 2020

View full text Add to dashboard Cite

Use of yttrium-90 (Y-90) is used for primary liver tumors and a handful of liver metastatic lesions. Y-90 treatment for metastatic adrenocortical carcinoma (ACC) to the liver is currently off-label, with one previously documented case report. In this case report, we present a 52-year-old woman with ACC and extensive liver metastatic disease. After failed chemotherapy, multidisciplinary discussion suggested potential Y-90 treatment for palliative purposes. After undergoing Y-90 treatment separately to the right and then the left hepatic lobes, subsequent patient visits demonstrated significantly improved clinical function as well as complete radiographic resolution of liver metastatic disease mainly from ACC. This case report demonstrates the potential efficacy of Y-90 for off-label uses in liver metastatic disease. This case and similar cases may open the door to a wide variety of potential indications for Y-90 treatment.

show abstract

“…Although RE treatment has been applied to a limited number of liver metastases of other primary tumors, tumor response close to HCC and colorectal metastasis has been reported (47). With the increase in the literature and experience, RE treatment may become a standard option in all types of primary and secondary liver tumors for which surgery is not intended as a general approach and which do not benefit from routine treatment (14,29,47).…”

Section: Erdoğan Ve Ark Radioembolizationmentioning

confidence: 99%

“…With the increase in the literature and experience, RE treatment may become a standard option in all types of primary and secondary liver tumors for which surgery is not intended as a general approach and which do not benefit from routine treatment (14,29,47).…”

Section: Erdoğan Ve Ark Radioembolizationmentioning

confidence: 99%

See 1 more Smart Citation

Radioembolization Treatment for Liver Cancer

Erdoğan¹,

Özdemir²,

Aydın³

2016

Bezmialem Science

View full text Add to dashboard Cite

Although curative treatment is surgery (resection/transplantation) and for small lesions ablative strategies, in primary liver carcinomas such as hepatocellular carcinoma and cholangiocellular carcinoma, palliative treatment is used for most of these patients because of lack of surgical options. These treatments are regional treatments such as transarterial chemoembolization, radiofrequency ablation, or microwave ablation and systemic treatments such as tyrosine kinase inhibitors. Surgery and chemotherapy are the main treatment options for metastatic liver tumors, particularly in colorectal tumors, although local treatment options are used for these patients. In recent years, transarterial radioembolization with yttrium-90 microsphere has emerged as a local treatment option in primary and metastatic liver tumors. The aim of this treatment is to provide an effective radiation dose distribution for the tumor in the liver tissue and to give the lowest dose in order to not harm the intact liver tissue. Radioembolization has proven to be as effective as other available palliative treatments in primary and secondary liver tumors and is a treatment method that is well tolerated. It has a risk for serious life-threatening complications, although this rate is low. Toxicity can be kept at a minimum with adequate technical and rigorous application in experienced hands and in accordance with multidisciplinarity. It is hoped that the effectiveness of radioembolization is further increased in the future by technological developments, researches on dosimetry, its use along with radiosensitizing agents, and various treatment combinations.Keywords: Radioembolization, Yttrium-90 microsphere, liver treatment IntroductionHepatocellular carcinoma (HCC) is one of the world's most common abdominal malignancies. Most patients have an underlying liver disease. The stage of tumor and the functional capacity of the liver determine the prognosis. A practical staging system based on the tumor burden, the liver function reserve, physical condition, and symptoms associated with cancer was developed by the Barcelona group (Barcelona Clinic Liver Cancer, BCLC). The tumor burden is determined by the number of tumors, size of tumor, portal vein invasion, or presence of extrahepatic metastasis. Here, the functional reserve of the liver is determined according to the Child-Pugh staging system (consists of serum albumin and bilirubin levels, the presence of acid and encephalopathy, prothrombin time/INR findings) and the physical condition is determined according to the performance classification of the Eastern Cooperative Oncology Group (ECOG). This staging system and accordingly, the overall treatment approach are summarized in Table 1 (1, 2).While only 30%-40% of patients are appropriate for curative treatment (resection, transplantation and ablation for small lesions), the vast majority of about 60% is in the middle (B) or advanced (C) stage (2). The general prognosis is poor in these patients with no potential curative treatment. Until n...

show abstract

Beyond Hepatocellular Carcinoma and Colorectal Metastasis: The Expanding Applications of Radioembolization

Cited by 11 publications

References 21 publications

Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry

Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry

Yttrium-90 Radioembolization of Metastatic Adrenocortical Carcinoma to the Liver following Systemic Chemotherapy and Surgical Resection of the Primary Lesion

Radioembolization Treatment for Liver Cancer

Contact Info

Product

Resources

About